Seeing Is Believing
Currently, out of the existing stock ratings of Leah Cann - 2708 which are a Buy (98.76%), 34 which are a Hold (1.24%)
Analyst Leah Cann works at BROOKLINE and is covering the Healthcare sector with 130 price targets and ratings displayed on 14 stocks. Previously, Leah Cann worked at OPPENHEIMER.
Leah Cann's average stock forecast success ratio is 41.67% with an average time for price targets to be met of 191.5 days.
Most recent stock forecast was given on MRNA, Moderna at 22-Jun-2022.
Analyst best performing recommendations are on SYRS.
The best stock recommendation documented was for MRNA (MODERNA) at 11/25/2020. The price target of $164 was fulfilled within 13 days with a profit of $54.82 (50.21%) receiving and performance score of 38.62.
Average potential price target upside
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average time for PT to be met
Performance score
Hold
260
$-11.46 (-4.22%)
260
16 days ago
17/17 (100%)
$43.7 (28.65%)
714
Buy
310
$38.54 (14.20%)
295
1 months 7 days ago
21/24 (87.5%)
$48.4 (31.11%)
728
Hold
223
$-48.46 (-17.85%)
208
1 months 7 days ago
13/17 (76.47%)
$15.67 (12.28%)
414
Hold
253
$-18.46 (-6.80%)
254
1 months 17 days ago
12/12 (100%)
$9.5 (5.69%)
190
Buy
280
$8.54 (3.15%)
280
1 months 27 days ago
13/21 (61.9%)
$44.69 (20.29%)
572
What Year was the first public recommendation made by Leah Cann?